Blood Biomarkers Predict Who Benefits Most from Dupilumab in COPD
A phase 3 trial analysis shows eosinophils and FeNO levels predict dupilumab response, supporting precision medicine for COPD.
Summary
A post-hoc analysis of the BOREAS phase 3 trial examined whether type 2 inflammation biomarkers could predict who benefits most from dupilumab in COPD patients. Among 939 patients with elevated blood eosinophils (≥300 cells/μL), dupilumab significantly reduced multiple inflammatory markers — including IgE, FeNO, eotaxin-3, and PARC — compared to placebo over 52 weeks. Crucially, patients with higher baseline blood eosinophil counts and FeNO levels experienced greater reductions in exacerbation risk. These findings suggest that specific, measurable biomarkers can identify COPD patients most likely to respond to dupilumab, paving the way for more targeted, biomarker-driven treatment strategies in a disease historically lacking precision therapy options.
Detailed Summary
COPD affects hundreds of millions worldwide and remains a leading cause of death, yet treatment options have been largely one-size-fits-all. A subset of COPD patients exhibits elevated type 2 inflammation — an immune pathway better known from asthma — and this subgroup faces higher exacerbation risk. Identifying who within this subgroup benefits most from targeted biologic therapy is a critical clinical question.
This post-hoc analysis leveraged data from BOREAS, a phase 3, double-blind, randomized controlled trial conducted across 275 sites in 24 countries. Patients with COPD and blood eosinophils ≥300 cells/μL were randomized 1:1 to dupilumab 300 mg every 2 weeks or placebo for 52 weeks. Researchers evaluated longitudinal changes in five type 2 biomarkers: blood eosinophil count, FeNO, serum eotaxin-3, total plasma IgE, and serum PARC.
At week 52, dupilumab produced substantially greater reductions across most biomarkers versus placebo. Total IgE fell by a median of 22.5% with dupilumab vs. 0.9% with placebo; FeNO dropped 28.6% vs. 6.9%; eotaxin-3 fell 8.8% vs. 0.4%; and PARC decreased 14.4% vs. 0.8%. Importantly, patients with higher baseline blood eosinophil counts (p=0.0056) and higher baseline FeNO (p=0.043) experienced greater reductions in exacerbation risk, establishing these as predictive — not just descriptive — biomarkers.
These findings carry significant implications for personalized COPD management. They suggest that routine measurement of eosinophils and FeNO before initiating biologic therapy could meaningfully stratify patients and optimize treatment decisions.
Caveats include the post-hoc nature of this analysis, which limits causal inference, and the fact that all enrolled patients already had elevated eosinophils, restricting generalizability to broader COPD populations. Funding from Sanofi and Regeneron — dupilumab's manufacturers — also warrants acknowledgment.
Key Findings
- Dupilumab reduced total IgE by 22.5% vs. 0.9% for placebo at 52 weeks in COPD patients.
- FeNO decreased 28.6% with dupilumab vs. 6.9% with placebo, signaling broad type 2 suppression.
- Higher baseline blood eosinophils predicted greater exacerbation risk reduction (p=0.0056).
- Higher baseline FeNO also predicted greater dupilumab benefit (p=0.043).
- Findings support biomarker-guided patient selection to optimize biologic therapy in COPD.
Methodology
Post-hoc analysis of BOREAS, a phase 3, double-blind, randomized, placebo-controlled trial with 939 patients across 275 sites in 24 countries. Patients with blood eosinophils ≥300 cells/μL were randomized 1:1 to dupilumab 300 mg Q2W or placebo for 52 weeks. Five type 2 inflammatory biomarkers were measured longitudinally in the safety population.
Study Limitations
This is a post-hoc, hypothesis-generating analysis rather than a pre-specified primary endpoint, limiting causal conclusions. All participants had elevated eosinophils at screening, so findings may not apply to the broader COPD population. Industry funding from the drug's manufacturers introduces potential bias.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.